Tango Therapeutics Inc
TNGX
NASDAQ
Biotechnology
$25.60
USD
-0.05 (-0.19%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.33B
Volume 1.4M
Revenue
$53.81M
TTM
+121.5%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-123.72M
TTM
+15.0%
YoY
Operating Cash Flow
$-143.90M
TTM
+2.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 3.2 | 53.8 | 0.0 | 0.0 | 0.0 |
YoY Growth | -84.0% | +363.6% | -100.0% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 3.2 | 53.8 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 11.3 | 8.9 | 9.8 | 15.2 | 22.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 44.1 | 39.7 | 41.9 | 48.8 | 59.8 |
Operating Income | -41.0 | 14.1 | -41.9 | -48.8 | -59.8 |
EBITDA | -40.3 | 14.6 | -41.4 | -48.3 | -59.4 |
Other Income / Expense | 0.9 | 0.7 | 1.4 | 1.1 | 0.7 |
Total Other Income / Expense | 2.1 | 1.8 | 3.1 | 3.3 | 4.4 |
Income Before Income Taxes | -38.8 | 15.9 | -38.8 | -45.5 | -55.3 |
Income Taxes | 0.0 | -0.0 | -0.1 | 0.0 | 0.0 |
Net Income | -38.9 | 15.9 | -38.7 | -45.5 | -55.3 |
Consolidated Net Income / Loss | -38.9 | 15.9 | -38.7 | -45.5 | -55.3 |
Net Income Attributable to Common Shareholders | -38.9 | 15.9 | -38.7 | -45.5 | -55.3 |
Basic EPS | -$0.35 | $0.14 | -$0.29 | -$0.32 | -$0.37 |
Diluted EPS | -$0.35 | $0.13 | -$0.31 | -$0.32 | -$0.37 |
Basic Shares Outstanding | 110.5M | 111.0M | 132.9M | 143.6M | 149.9M |
Diluted Shares Outstanding | 110.5M | 117.8M | 126.0M | 143.6M | 149.9M |